Quick Answer
In June 2026 the U.S. Food and Drug Administration added bemotrizinol, a UV filter long used in Europe, to the over-the-counter sunscreen monograph at concentr…
What the bemotrizinol decision actually changed, and what it does not mean for peptides
Producto ar peptídeo ya mar dätä Amp Peptide Hmä enmendó 'nar monografía OTC existente. hingi bí 'nar 'ra'yo nthädi hä ar medicamento, ne creó ni 'na jar vía, categoría wa precedente pa 'na péptido.
ar instrumento importa ngetho gi mä ar carga ar evidencia. Bemotrizinol bi 'yot'e monografía M020 a través de 'nar ya ngäts'i administrativa jár sección 505G(b)(1) ar ar ley ar nts'ot'i ne ar medicamentos, publicado en ar Registro Federal notificación ar 10 June 2026. ar proceso comenzó ko 'nar Tier 1 OTC Monograph Order ar DSM Nutritional Products LLC, anunciado jar ar Disyembre 2025 ya propuesto, and the final order grants that company and its licensees an 18-month exclusivity period from the effective date, Komo bí establece en the final administrative order itself.
The conditions of use show how specific a monograph entry is. Under the amended monograph, a finished product must reach a minimum SPF of 2, may not combine bemotrizinol with aminobenzoic acid or trolamine salicylate, and is limited to oil, lotion, cream, gel, butter, paste, ointment, stick and spray forms where the propellant never contacts the formulation. FDA’s own framing, including the HHS Secretary’s comment that the ingredient “has been used safely in Europe for decades,” appears in FDA’s announcement.
Read the order as a QC reviewer and the lesson is plain. FDA rejected the aerosol spray data not because the ingredient failed, but because the stability programme behind it was too thin to evaluate: ten weeks of data, no release-time assay results, uncertain container impermeability, and storage conditions without humidity control. The submission was judged on the completeness of its evidence, not on the promise of its molecule.
Three groups read this differently. Suppliers see a reminder that the dossier is the product. Brand developers see a longer qualification checklist. QC and regulatory affairs, where most of our readers sit, see the actual work: deciding what evidence to demand and how to check that it connects.
Classify before you test: cosmetic, OTC drug, or both
Classification is a claims decision, not a property of the molecule. A peptide is not automatically a drug, and it is not automatically a cosmetic.
FDA decides that by intended use. 'nar cosmético ge 'nar xeni Nthuts'i da t'uni komongu pa ar limpieza, embellecimiento, 'ñäni ar atractivo alterar apariencia. 'nar droga ge 'nar xeni Nthuts'i destinado ar diagnosticar, curar, mitigar, japi wa da mä 'met'o enfermedad, wa da to ar estructura wa función komongu. 'nar producto ga̲ yoho nsa̲di njapu'befi previsto da tsoni ga̲ yoho conjuntos requisitos, ne ar ngäts'i 'nar cosmecéutico 'nar pe̲ts'i ni 'na jar bo̲ni ja ir 'rangu̲di. ley.
da pe̲ts'i consecuencias directas pa nä'ä gi da sostener. requisito justificación ntsuni adecuada MoCRA obliga ar jä'i responsable da zeti ya registros apoyan ar Ts'ut'ubi, pe nixi ar ley nixi regulaciones ar FDA prescrimen Temu̲ ya pruebas ejecutar. �, renovación ar registro ar instalación ya yoho ya je̲ya ne listado ar 'befi productos da t'uni jar instalaciones ne productos cosméticos, and serious adverse events must be reported within the 15-business-day serious adverse event clock.
Before you commission a single study, answer three questions in writing:
-
What exactly will the label and marketing claim the product does?
-
Does any claim cross into affecting structure or function, or preventing a condition?
-
If the answer to question two is yes, which drug requirements will the product carry?
Confirm the classification with regulatory counsel before the evidence plan is fixed. Reclassifying after the studies are designed usually means repeating them.
The five things a peptide data package must prove
The framework is not ours to invent, and it is not an FDA rule for cosmetics. It follows the logic of ICH Q2(R2)’s fit-for-purpose standard, which requires a validation protocol written before the study and treats identity, pureza, assay and impurity testing as separate procedure types. The edition in force is the March 2024 final version, which replaced the older Q2(R1) framework. For cosmetic peptides this is borrowed logic, applied because it works, not because the law demands it.
The scope of “peptide” is wider than many formulators assume. A 2026 peer-reviewed safety framework for cosmetic peptides defines a peptide as a polymer of up to 40 aminoácidos, roughly 4.4 kDa, and notes that historically cosmetic peptides have sat below 500 Da, around five residues. It also lists the modifications that must be defined rather than assumed: D — aminoácidos, glicosilación, and fatty-acyl conjugation at the N-terminus.
Identidad: confirming the molecule, not the trade name
Identity is a separate procedure type under Q2(R2), and it is the claim most often satisfied by a trade name and a certificate. That is not identity.
P, i. d; a. Mass spectrometry also confirms mass and fragmentation pattern, a, r.
The sequence itself belongs in the package as a change-controlled document with a version history. c, o, n.
Purity: what an HPLC percentage leaves out
f i r. It is not a property of the lot in isolation.
The number means something only alongside the method it came from: columna, gradiente, longitud onda detección, reference standard and the lot-linked chromatogram. Without those, a reviewer cannot re-examine the result, and a 98 percent figure cannot be distinguished from a 95 percent one measured under different conditions. Area percent also cannot separate co-eluting truncation from oxidation without orthogonal evidence, which is why the chromatogram matters more than the headline.
Ask for the chromatogram and the method description, not the summary number. If the supplier cannot produce a lot-specific chromatogram, the purity claim is unverifiable regardless of its value. The validation protocol Q2(R2) requires should also exist before the study, not be reconstructed afterwards.
Content and counterion: why net peptide per milligram is a separate number
Net peptide content is the mass of peptide per milligram of material, and it is not the same as purity. A 95 percent pure lot can still deliver far less peptide per milligram than the formulator assumes.
Two things sit between purity and content. Ar dehe, measured by Karl Fischer, d. Counter ions are an impurity class to characterise, and the framework names acetic acid as an example. In practice the counterion is often trifluoroacetate, and trifluoroacetate is heavy: it adds mass that is not peptide. Our own cosmetic peptide documentation treats trifluoroacetate as the default and offers acetate, chloride and ammonium exchange, because the counterion changes the net peptide figure per milligram and the formulator needs the number that matches the salt actually shipped. Planetpeptide
Determine peptide content with a suitable quantitative method, such as validated amino-acid analysis, qNMR or another justified assay. State the water, counterion and reporting basis where relevant; amino-acid analysis is not the only permissible method.
Stability: designing the study before the launch date
Stability is a study design problem, and the design has to be fixed before the launch date is set. Retrofitting timepoints after a launch plan exists is how programmes end up with data that cannot support the shelf life claimed.
The stress-testing logic in ICH Q1A(R2) is the right starting framework. ICH Q1A(R2)’s stress-testing purpose is to identify likely degradation products, establish degradation pathways and intrinsic stability, and validate that the analytical methods can actually detect change. Conditions include temperatures 10 °C above the accelerated condition, humidity, oxidation, photolysis, and hydrolysis across a wide pH range.
Design the finished-formulation stability study around its composition, packaging, storage conditions and proposed shelf life. Pharmaceutical Q1A(R2) conditions may inform a study where justified; its submission durations, batch counts and significant-change definitions are not automatic cosmetic requirements.
These are drug-substance and drug-product conditions, borrowed as a framework. Cosmetics are not bound by them, and a cosmetic peptide programme can justify a lighter design. What it cannot do is skip the design step. Decide the storage conditions, the timepoints, the attributes tested and the acceptance criteria in writing, and make sure the methods used are stability-indicating before the first sample goes on test.
Callout: what the sunscreen order shows about thin stability data. FDA’s rejection of the aerosol spray data turned on exactly these elements: too short a study, no release-time results, storage conditions without humidity, and assay results close to the acceptance limit with no baseline to interpret them. A cosmetic peptide dossier will not be reviewed by FDA in the same way, but the same gaps make a package unreadable to any technical reviewer.
Where the peptide’s function can be measured, Q5C’s potency logic is worth borrowing: when intended use is linked to a measurable biological activity, potency testing belongs in the stability studies. Q, 5, C.
Labeling: getting the name and the order right
For US ingredient declarations, U, t. i, l.
i. c, e 1 h 1 percent. t (ne) h, u.
The minimum connected data package, field by field
u. 'nar certificado análisis jar ár nt'ot'ise̲ ge 'nar resumen, ne 'nar resumen hingi ge 'nar paquete.
Ar hilo conexión ar 'mui ar datos. guía ya datos — 'mui ar MHRA establece ar atribuible, legible, contemporáneo, original, Principios exactos, extendidos ya completo, consistente, duradero ne disponible, ne hmä otho ni 'na jar diferencia ja ya expectativas 'na ya acrónimo da utiliza. Datos crudos ge ar registro original. nu'bu̲ ar cromatograma ja ar dossier hingi ar tsa̲ da rastrear asta ar carrera nä'ä bí produjo, ar registro hingi 'bu̲i conectado.
Callout: ar respuesta ho̲ntho CoA. Nu'bu̲ 'nar proveedor thädi 'nar solicitud documentación ko 'nar certificado ne ho̲ntho mä, tratar Peptide Info Manufacturer komongu 'nar respuesta incompleta en lugar de 'nar negación. �.
�. Part 11’s records-equivalence test x, k. a, but a supplier whose records would fail it is a supplier whose data you will struggle to audit.
Qualifying a peptide supplier before a U.S. launch
Cosmetic peptide supplier qualification comes down to one question: can this supplier produce lot-specific evidence on request, and does the evidence connect? Facility size and portfolio breadth do not answer it.
Ma documentación estándar ar péptidos cosméticos mfa̲ts'i 'bu̲i HPLC analítico pa pureza, mass spectrometry for identity, ne contenido peptídicos junto con 'nar certificado análisis, cromatograma ne espectro masa pa ar lote. análisis contraiones, contenido ar dehe ya Karl Fischer, pruebas endotoxinas ne rotación óptica gi 'bu̲hu̲ da 'mui komongu ya adiciones opcionales. nä'ä importa jar calificación hingi ge ar Nthuts'i verificación pe nu'bu̲ tsa̲ da uni nä'ä pa ar lote específico ne nu'bu̲ ya descripciones ar nt'ot'e subyacentes ya incluidos.
hñu ya comprobaciones recomendamos ga OT'UJE 'be̲tho ga OT'UJE 'nar pedido:
-
solicite 'nar paquete específico mucho, hingi 'nar plantilla. Gi 'ya̲ni ar cromatograma, espectro, ne ar nt'uni contenido pa ar lote da recibiría, ne gí hñeti ha ár 'bede ya lote a través de ya documento. proveedor polipéptido
-
Pregunte Temu̲ ar verifica ar secuencia. A change-controlled sequence document with modification history tells you whether an N-terminal change would reach you as a new identity or as a silent substitution.
-
Ask what happens at scale-up. Purity and content can shift between milligram and kilogram scale, so ask for the analytical results from the largest scale run available and for the per-step testing that supports them.
Callout: tech-transfer risk. A package that is complete at small scale and silent at production scale leaves the brand developer carrying the risk. Ask which analytical results exist at the scale you will buy, and whether the method transfers with the process.
The decision rule: what to require before you commit
Do not commit to a peptide launch on a purity figure. Commit when the five claims are each supported by lot-specific, connected evidence, and not before.
Before commercial commitment, resolve safety, identity and other critical evidence gaps. Plan remaining development work with milestones appropriate to the stage; an early sample order need not already include every finished-formulation study.
Jar práctica, that means an ordered sequence of requirements:
-
Written classification of the product and its claims, confirmed with regulatory counsel.
-
A change-controlled sequence document including every modification.
-
Identity by mass confirmation plus one orthogonal technique, ja ar lote.
-
Purity with the method description and the lot-linked chromatogram.
-
Net peptide content by a suitable quantitative method, with the reporting basis stated.
-
A stability protocol agreed in writing before the launch date is fixed, with stability-indicating methods.
-
A labeling review covering legally appropriate ingredient names and declaration order.
-
Records that trace from the certificate back to raw data.
nt'a̲ni frecuentes
Does the bemotrizinol decision create a route for peptide actives in the U.S.?
No. The order amended an existing OTC sunscreen monograph under section 505G(b)(1) and applies to one UV filter under defined conditions. It establishes no pathway, category or precedent for peptides, cosmetic or otherwise. The transferable lesson is the evidence standard, not the legal route.
Is a peptide automatically regulated as a drug in the U.S.?
No. FDA classifies by intended use, so the same peptide can be a cosmetic, a drug, or both depending on what the product claims. A product with both cosmetic and drug intended uses must comply with both sets of requirements, and there is no “cosmeceutical” category in U.S. ley.
Ar 98 'nar nthebe 'bebe ma HPLC pureza xingu pa 'nar U.E.. launch?
It is one of five claims, and on its own it is not enough. A purity figure says nothing about identity, Contenido neto peptídico, nzäm'bu wa nu'bu̲ ar nt'ot'e mi apto pa ár 'mu̲i. Pide ar cromatograma, descripción ar nt'ot'e ne ar nt'uni contenido junto a nä'ä.
Tange diferencia entre pureza ne contenido neto ar peptídico?
Pureza ge 'nar medida ir nge ar cuánto ar he̲'mi detectado ge ar péptido objetivo. Contenido neto ar péptido ge ar masa ar péptido ya miligramo ar hñei, después ja da ar dehe ne contraión. 'nar lote mextha pureza ko 'nar contraión hñei to ofrecer sustancialmente menos péptido ya miligramo nä'ä sugiere ndo'yo pureza.
¿pe̲ts'i ya péptidos cosméticos pe̲ts'i da tsoni requisitos nzäm'bu ICH?
No. ICH Q1A(R2) ne Q5C ya directrices droga ne productos biológicos ne hingi ya legalmente vinculantes dige ya cosméticos. ár lógica Tobe vale dá dí ntsa̲ da prestado, getho 'nar nthuts'i nkohi nzäm'bu diseñado esos ndui thädi ya nt'a̲ni 'nar revisor técnico bí preguntará.
Temu̲ gi incluir 'nar certificado análisis péptido?
At minimum, i, ya resultados analíticos pa identidad, pureza ne contenido, ya nt'ot'e utilizados, and the specification each result is measured against. It should be accompanied by the lot-specific chromatogram and mass spectrum, and traceable to the underlying raw data.
Njäts'i nu'bu
The bemotrizinol milestone is worth reading closely, but not as a sign that peptide access just got easier. It is a demonstration that U.S. access follows a connected, claim-by-claim data package, and that a submission is judged on the completeness of its evidence rather than the promise of its molecule. For peptide developers, that is a higher bar than most current documentation clears, and it is the right one to adopt before a launch date is set.
The practical takeaway is the decision rule: five claims, five sets of evidence, one connected record per lot. Classification first, then identity, pureza, content, Nzäm'bu ne idoneidad ensayo, each with the method and the raw data behind it. A supplier who can meet that standard for the lot you are buying is a supplier you can build a U.S. launch on.
At MOL Changes we supply cosmetic peptides from milligram research quantities to kilogram scale, with analytical HPLC, mass spectrometry and peptide content results issued against the lot, and counterion, water content and endotoxin testing available where the application needs them. If you are assembling a documentation package ahead of a U.S. launch, send us your requirements and we will walk through what the lot records contain.
divulgación ar editor: M. O; availability and performance for a specific construct require project-specific evidence.
